Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.78 |
| ▸ | LTA4H | P09960 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL20328417 | 0.88 | — | — | |
| Anisole SCHEMBL1205 | 0.88 | — | — | |
| Anisole SCHEMBL30601749 | 0.88 | — | — | |
| Anisole SCHEMBL8472521 | 0.88 | CA4 (1.00) | CA4LTA4HCA12CA1CA2 | |
| Anisole SCHEMBL10721106 | 0.88 | CA4 (1.00) | CA4LTA4HCA12CA1CA2 | |
| Anisole SCHEMBL2493788 | 0.88 | CA4 (1.00) | CA4LTA4HCA12CA1CA2 | |
| Anisole SCHEMBL28813915 | 0.88 | CA4 (1.00) | CA4LTA4HCA12CA1CA2 | |
| Anisole SCHEMBL3630332 | 0.86 | CA4 (0.82) | CA4LTA4HCA12CA1CA2 | |
| Anisole SCHEMBL2336805 | 0.85 | — | — | |
| Anisole SCHEMBL5377903 | 0.85 | CA4 (0.93) | CA4LTA4HCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007122628-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE CEFOTETAN DISODIUM | LUPIN LIMITED (IN) | 2007-11-01 | — | — | WO | claimed |
| CN-105481848-A | Cefotetan active ester and high purity cefotetan acid preparation method | CHONGQINGG TIANDI PHARMACEUTICAL CO LTD CHINA | 2016-04-13 | — | — | CN | disclosed |
| CN-103524449-B | Method for synthesizing 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide | SHANDONG BOYUAN PHARMACEUTICAL CO LTD | 2015-06-03 | — | — | CN | disclosed |
| CN-103524449-A | Method for synthesizing 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide | SHANDONG BOYUAN PHARMACEUTICAL CO LTD | 2014-01-22 | — | — | CN | disclosed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| CN-102718780-A | Preparation method of cefmetazole sodium | WEINA LIU | 2012-10-10 | — | — | CN | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8178535-B2 | Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| WO-2009090054-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090055-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007122628-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE CEFOTETAN DISODIUM | LUPIN LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122628-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE CEFOTETAN DISODIUM | LUPIN LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-0321187-B1 | 6-(SUBSTITUTED METHYLENE)PENEMS | BEECHAM GROUP PLC (GB) | 1993-07-28 | — | — | EP | disclosed |
| WO-1993003042-A1 | 6-ETHYLIDENE PENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1993-02-18 | — | — | WO | disclosed |
| US-4931434-A | Penem compounds | BEECHAM GROUP P.L.C. (GB) | 1990-06-05 | — | — | US | disclosed |
| EP-0321187-A1 | 6-(Substituted methylene)penems | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293482-A1 | Process for Preparing Benzodiazepines | CNR1, SIGMAR1, GABRA3 | CA4 1114/4885LTA4H 2915/4885CA12 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.